·The only selective free water diuretic currently marketed in China that does not excrete sodium ions ·The only drug currently available that can effectively slow the progression of autosomal dominant polycystic kidney disease ·Recommended by multiple authoritative guidelines, including the "Chinese Guidelines for the Diagnosis and Treatment of Heart Failure", "Chinese Expert Consensus on Ion Management in Patients with Heart Failure", "Chinese Expert Consensus on the Comprehensive Management of Patients with Worsening Chronic Heart Failure 2022", "2023 Chinese Expert Consensus on Hyponatremia", and the "Clinical Practice Guidelines for the Diagnosis and Treatment of Cardiorenal Syndrome (2023 Edition)"

*For contraindications and adverse reactions, please see the package insert

·A new fourth-generation basic carbohydrate and electrolyte infusion ·First generic in China, featuring zinc ·Recommended for diagnosis and treatment in multiple authoritative guidelines, including the "Evaluation and Analysis of Drug-Use in Hospitals of China" ·Benefiting over a million patients

*For contraindications and adverse reactions, please see the package insert

·Iopamidol is the world's first non-ionic iodinated contrast agent, offering clearer enhanced imaging advantages ·Covers clinical application areas such as neuroradiology, arthrogram, and DSA

*For contraindications and adverse reactions, please see the package insert

·An oral small-molecule JAK inhibitor that regulates inflammation signaling pathways ·Approved indications include rheumatoid arthritis, psoriatic arthropathy, and ankylosing spondylitis

*For contraindications and adverse reactions, please see the package insert

·A dipeptidyl peptidase-4 inhibitor (DPP-4i) for the treatment of type 2 diabetes mellitus ·Offers advantages such as blood sugar control, low risk of hypoglycaemia, and cardiovascular protection

*For contraindications and adverse reactions, please see the package insert

·The first lipid microsphere carrier-based targeted drug in China ·Indications cover chronic arterial occlusive disease, antithrombotic therapy for organ transplant, congenital heart disease, and adjuvant therapy for chronic hepatitis ·Included in national diagnosis and treatment guidelines and textbooks such as the "Chinese Expert Consensus on PG Drugs for the Treatment of CKD" and the "Chinese Expert Consensus on Prostaglandin Drugs for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes" ·Honored as a National Key New Product and a National Torch Program project, and selected as a billion-level major product in the Beijing G20 Project

*For contraindications and adverse reactions, please see the package insert

·The first lipid microsphere carrier-based targeted analgesic in China ·Recommended as a basic perioperative analgesic in multiple authoritative guidelines, including the "Guidelines for Postoperative Pain Management" ·Honored as one of the "Top 10 Leading Brands in the Chinese Pharmaceutical Industry"

*For contraindications and adverse reactions, please see the package insert

·The first domestically produced oral prostacyclin derivative ·Recommended in guidelines such as the "European Society of Cardiology Guidelines for Pulmonary Hypertension" and the "American College of Chest Physicians Evidence-Based Guidelines", becoming a core medication in the field of peripheral angiopathy ·Selected for the "2024 China Pharmaceutical Brand List"

*For contraindications and adverse reactions, please see the package insert

·First domestically produced rivastigmine transdermal patch ·Specially designed for patients with Alzheimer's disease, with its core advantage being transdermal drug delivery technology ·The convenient once-daily patch significantly improves patient adherence, especially for elderly individuals with memory decline or mobility issues

*For contraindications and adverse reactions, please see the package insert